Journal Report

MULTIPLE SCLEROSIS JOURNAL

Download PDF
Journal Information
Journal Title
MULTIPLE SCLEROSIS JOURNAL
Publisher
SAGE PUBLICATIONS LTD
ISSN
1352-4585
E-ISSN
1477-0970
Database
Clarivate
Domain
Health Sciences, Life Sciences, Physical Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Myelin oligodendrocyte glycoprotein antibody–associated disease in a modern, population-based cohort
Annette M. Langer-Gould, Jason N. Scott, Jessica B. Smith et al.
2026-11-5
DOI: 10.1177/13524585261499525
Pelvic neurology meets multiple sclerosis
Sarah L. Wright
2026-11-4
DOI: 10.1177/13524585261501838
Rectal pallesthesia as a novel symptom of multiple sclerosis: A case report
Matthew N. Lowy, Stanley Levy
2026-11-4
DOI: 10.1177/13524585261501833
Lower recorded prevalence of Alzheimer’s disease in natalizumab-exposed older adults with multiple sclerosis: A hypothesis-generating observation
Afsaneh Shirani, Barbara E. Stopschinski, Joachim Herz et al.
2026-11-3
DOI: 10.1177/13524585261499995
Multiple sclerosis relapse redefined: Effect of an MRI-supported relapse criterion on ublituximab outcomes in the ULTIMATE I and II trials
Stephen C. Krieger, Karthik Bodhinathan, Yihuan Xu et al.
2026-11-3
DOI: 10.1177/13524585261499629
Emergence of natalizumab anti-drug antibodies during extended interval dosing in a patient with multiple sclerosis: A case report
Liza M. Y. Gelissen, Stefan P. H. van den Berg, Thomas P. C. Dorlo et al.
2026-11-2
DOI: 10.1177/13524585261500350
Ocrelizumab treatment and disability progression in non-Hispanic Black and Hispanic or Latino individuals with relapsing multiple sclerosis: A post hoc analysis of the OPERA I and II trials
Lilyana Amezcua, Devi Sai Sri Kavya Boorgu, Jake Oxendine et al.
2026-10-28
DOI: 10.1177/13524585261496124
Multimodal effects of CD40L blockade in multiple sclerosis: Insights from preclinical and clinical studies
Ismail Muwenda, Joshua S. Mytych, Ekdanai Uawithya et al.
2026-10-27
DOI: 10.1177/13524585261490852
Availability of resources to apply the 2024 McDonald criteria: A global perspective
Natalia Gómez-Salazar, Paola A. Ortíz-Salas, Rebecca Wicklein et al.
2026-10-23
DOI: 10.1177/13524585261493315
Rituximab versus ocrelizumab: When inference exceeds the evidence
Fredrik Piehl, Thomas Frisell, Kjell-Morten Myhr et al.
2026-10-18
DOI: 10.1177/13524585261496111
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 10, 2026 01:43